Across TCGA pan-cancer cohorts, PSMD12 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PSMD12 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PSMD12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and PRAD are the cancer types where PSMD12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.174	0.735	<.001	28	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.029	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.188	0.669	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PSMD12 tumor-vs-normal RNA expression · all PSMD12 data types